Zobrazeno 1 - 10
of 112
pro vyhledávání: '"RUIGUANG ZHANG"'
Autor:
Lianxi Song, MD, Huan Yan, MD, Qinqin Xu, MD, Chunhua Zhou, MD, Juan Liang, MD, Shaoding Lin, MD, Ruiguang Zhang, MD, Juan Yu, MD, Yang Xia, MD, Nong Yang, MD, Liang Zeng, MD, Yongchang Zhang, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100729- (2024)
Introduction: Despite receiving alectinib therapy, patients with ALK-positive NSCLC remain at risk of central nervous system (CNS) progression. Our retrospective study aimed to identify baseline clinical and molecular factors associated with the risk
Externí odkaz:
https://doaj.org/article/9a7d69fccf564f6b938023b45a9ec0cb
Autor:
Haoyue Qin, Zhe Huang, Huan Yan, Lianxi Song, Liang Zeng, Qinqin Xu, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Xing Zhang, Fan Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Xiaorong Dong, Nong Yang, Yongchang Zhang
Publikováno v:
iScience, Vol 27, Iss 10, Pp 110910- (2024)
Summary: This retrospective study demonstrated that patients with advanced non-small cell lung cancer who experienced any-grade or grade 1–2 immune-related adverse events (irAEs) with immune checkpoint inhibitor plus chemotherapy (ICI+Chemo) as fir
Externí odkaz:
https://doaj.org/article/59695238bc9c432d948adfe9758adaf2
Autor:
Lichao Liu, Jian Wang, Ying Wang, Lingjuan Chen, Ling Peng, Yawen Bin, Peng Ding, Ruiguang Zhang, Fan Tong, Xiaorong Dong
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)
Abstract Background Brain metastasis is one of the main causes of recurrence and death in non-small cell lung cancer (NSCLC). Although radiotherapy is the main local therapy for brain metastasis, it is inevitable that some cancer cells become resista
Externí odkaz:
https://doaj.org/article/836e2093d6fa48c1b229690be5a03dc9
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 2, Pp 102215- (2024)
Externí odkaz:
https://doaj.org/article/e39ae3bd3f0b42508f133243ae8fdcea
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
ObjectiveThe aims of this survey were to investigate the public awareness of drug clinical trials (DCTs) and willingness to participate the DCTs, and provide references for propaganda and science popularization of DCTs.MethodsA self-designed question
Externí odkaz:
https://doaj.org/article/00c93433d9e74c4ab46d8db7c9e36bd3
Publikováno v:
Orthopaedic Surgery, Vol 15, Iss 6, Pp 1549-1555 (2023)
Objective Laminectomy has been widely used for intraspinal tumor resection. However, the tilted spinous process and narrow lateral laminae of the thoracic spine along with the hypertrophic ligamentum flavum of the lumbar spine pose certain problems f
Externí odkaz:
https://doaj.org/article/d075b2d1971b48f9a41f5d6be26b46e9
Autor:
Chaonan Zhang, Cheng Wei, Xingqi Huang, Changxin Hou, Chuan Liu, Shu Zhang, Zilong Zhao, Yafan Liu, Ruiguang Zhang, Lei Zhou, Ying Li, Xubo Yuan, Jianning Zhang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Contact sports athletes and military personnel who suffered a repetitive mild traumatic brain injury (rmTBI) are at high risk of neurodegenerative diseases such as advanced dementia and chronic traumatic encephalopathy (CTE). Howe
Externí odkaz:
https://doaj.org/article/0e9a7fbc928844c799c93dedefd6b494
Autor:
Ling Peng, Yawen Bin, Peng Ding, Lingjuan Chen, Hao Zeng, Zelong Xu, Liyan Ji, Xuan Gao, Pian Liu, Ye Wang, Sheng Zhang, Zhongxing Liao, Xuefeng Xia, Ruiguang Zhang, Fan Tong, Xiaorong Dong
Publikováno v:
Cancer Communications, Vol 43, Iss 5, Pp 625-629 (2023)
Externí odkaz:
https://doaj.org/article/25375e8ebf144ab78f99ce2c020c672d
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or seco
Externí odkaz:
https://doaj.org/article/1406ed17fbd74e9ba23e956e48eec291
Autor:
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou, Jiexia Zhang, Zhengbo Song, Nong Yang
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. Our retrospective
Externí odkaz:
https://doaj.org/article/8d3d55c715a84c45ade8c62b76e84bcc